Apart from the application of naked VEGF-mRNA therapeutics for heart failure treatment from AstraZeneca (AZD8601, in partnership with Moderna), most protein replacement therapy involving LNP-mRNA medicines has primarily undergone intensive preclinical exploration. This evidence concerns the gene VEGFA and heart failure.